Department of Toxicology, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic.
J Enzyme Inhib Med Chem. 2013 Aug;28(4):753-7. doi: 10.3109/14756366.2012.681652. Epub 2012 Apr 30.
The ability of a novel bispyridinium oxime K203 to reactivate VX agent-inhibited acetylcholinesterase was compared with the reactivating efficacy of four commonly used oximes (obidoxime, trimedoxime, methoxime, HI-6) using in vivo model. Our results showed that the reactivating efficacy of the oxime HI-6 is higher than the reactivating efficacy of the other oximes studied including the oxime K203 although the differrences between the oxime HI-6 and some other oximes are not significant, especially in the blood. Based on the obtained data, we can conclude that the antidotal treatment involving the oxime HI-6 brings the higher benefit for the antidotal treatment of acute poisonings with VX agent than other oximes.
新型双吡啶肟 K203 复活 VX 剂抑制的乙酰胆碱酯酶的能力，与四种常用肟类化合物（obidoxime、trimedoxime、methoxime、HI-6）在体内模型中的复活效果进行了比较。我们的结果表明，肟类化合物 HI-6 的复活效果高于其他研究肟类化合物的复活效果，包括肟类化合物 K203，尽管肟类化合物 HI-6 与其他一些肟类化合物之间的差异并不显著，特别是在血液中。根据获得的数据，我们可以得出结论，肟类化合物 HI-6 的解毒治疗比其他肟类化合物对 VX 剂急性中毒的解毒治疗带来更高的效益。
